Generalized lichen planus‐like eruption due to acetylsalicylic acid

Ruiz‐Villaverde, Ricardo; Melguizo, J. Blasco; Guil, Francisco Mendoza; Sánchez, MC Martín; Sintes, R. Naranjo

doi:10.1046/j.1468-3083.2003.00614_2.x

Cited by 15 publications

(6 citation statements)

References 6 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Drugs from the class of Renin‐Angiotensin‐Aldosterone System inhibitors (diuretics, angiotensin II receptor typ 1 blockers and angiotensin‐converting enzyme blockers) were also found to lead to LDE in a total of 12 reports (3.7%) 77,92–98 . Single cases of LDE were caused by other drugs given for cardiovascular diseases (antiplatelet agents, antisympathotonics, prostaglandin, nicotinamide and antiarrhythmics) in a total of 15 (4.6%) cases there of eight cases (2.5%) were caused by dilitiazem 99–111 …”

Section: Resultsmentioning

confidence: 99%

“…77,[92][93][94][95][96][97][98] Single cases of LDE were caused by other drugs given for cardiovascular diseases (antiplatelet agents, antisympathotonics, prostaglandin, nicotinamide and antiarrhythmics) in a total of 15 (4.6%) cases there of eight cases (2.5%) were caused by dilitiazem. [99][100][101][102][103][104][105][106][107][108][109][110][111] Furthermore, six cases (1.9%) of LDE induced by gout medications (uricostatics and alkaloids) were identified. [112][113][114] Also, vaccines have been reported to cause LDE in a total of 8 (2.5%) cases (hepatitis A/B, influenza, herpes zoster, human papillomavirus) [115][116][117][118][119] Four cases (1.24%) of Capecitabine-induced LDE were reported.…”

Section: Culprit Medicationsmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications

Maul

Guillet

Oschmann

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

Cutaneous lichenoid drug eruptions (LDE) are adverse drug reactions (ADR) characterized by symmetric, erythematous, violaceous papules reminiscent but rarely fully characteristic of lichen planus (LP). We aimed to analyse the literature describing cases of LDE within the last 20 years to provide additional insight into culprit drugs, typical latency to onset of the eruption, the spectrum of clinical presentations, severity and management. A literature search was conducted in MEDLINE between January 2000 and 27 January 2021. The keywords ‘lichenoid drug rash’ and ‘lichenoid drug eruption’ were used. Cases were included if LDE diagnosis was made, and culprit drugs were identified. A total of 323 cases with LDE were identified from 163 published case reports and studies. The mean patient age was 58.5 years (1 month to 92 years), and 135 patients (41.8%) were female. Checkpoint inhibitors (CKI) were the most frequently reported culprit drugs (136 cases; 42.1%), followed by tyrosine kinase inhibitors (TKI) (39 cases; 12.0%) and anti‐TNF‐α‐monoclonal antibodies (13 cases; 4.0%). The latency between initiation of the drug and manifestation was 15.7 weeks (range: 0.1–208 weeks). After discontinuing the culprit drug, the median time to resolution was 14.2 weeks (range: 0.71–416 weeks). One hundred thirty‐six patients (42.1%) were treated with topical, and 54 patients (16.7%) with systemic glucocorticoids. Overall, we conclude that, albeit rare, LDE is challenging to diagnose ADR induced by mostly CKI, TKI, and biologics. Treatment modalities resemble that of lichen planus, and the culprit drugs had to be discontinued in only 26%, which is low compared with other types of adverse drug reactions. This is probably due to the low risk of aggravation (e.g. toxic epidermal necrolysis) if the drug is continued and the benefit/risk ratio favouring the drug, as is often the case in cancer therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Culprit Medicationsmentioning

confidence: 99%

Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications

Maul

Guillet

Oschmann

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Thus, we think that in our patient lichen planus had begun twenty years ago but tended to be chronic, with fluctuations in signs and symptoms over time. Moreover, in our opinion, medications of the patient, which were metoprolol, acetylsalicylic acid and clopidogrel might have played a role in aggravating the condition, since these drugs are potential triggers for lichen planus [1,9,10]. On the other hand, the main limitation of our case report is that, we could not prove the diagnosis of lichen planus with histopathology.…”

Section: Discussionmentioning

confidence: 71%

Nail lichen planus: a patient with atypical presentation

Yorulmaz¹,

Bulut²,

Yalçın³

2019

Our Dermatol Online

View full text Add to dashboard Cite

Lichen planus is a common chronic inflammatory dermatosis characterized by small, violaceous, flat-topped polygonal papules mostly seen on the flexural wrists and ankles. Several variants of lichen planus have been described based on either morphological appearance, configuration of the lesions or site of the involvement. Moreover, lichen planus is a distinctive dermatosis, in which mucosal or nail involvement may develop in the absence of cutaneous involvement. It has been estimated that nails are affected up to 10% of all patients with lichen planus. The most specific and unique nail finding of lichen planus is the pterygium formation. Pterygium unguis also known as dorsal pterygium refers to a V-shaped extension of the proximal nail fold over the nail plate, which eventually produces permanent onychatrophy. Here, we describe a patient with pterygium unguis, who also manifests atypical mucosal and cutaneous lesions of lichen planus.

show abstract

“…Sufficient evidence exists to support the thesis that betablockers, methyldopa, penicillamine, quinidine and quinine may play a pathogenic role and are potential triggers of the disease [7]. Given the available epidemiologic evidence, nonsteroidal antiinflammatory drugs could also be considered as a potential causative agents [1,11].…”

Section: Introductionmentioning

confidence: 99%